Tessa Therapeutics Pte Ltd

48 articles about Tessa Therapeutics Pte Ltd

• Tessa Therapeutics Announces Positive Data from Phase 2 Trial of Autologous CD30-CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma at 2021 ASH Annual Meeting

  12/13/2021

  Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced clinical data from the pilot stage of the ongoing Phase 2 CHARIOT trial (NCT04268706) of TT11, the Company’s autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy.

• Tessa Therapeutics Showcases Positive Clinical Data from Phase 1 Study of “Off the Shelf” CD30 Cell Therapy at 2021 Annual Meeting of American Society of Hematology (ASH)

  12/11/2021

  Tessa Therapeutics Ltd., a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced clinical data from an ongoing Phase 1 study of TT11X, an allogeneic “off the shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy being co-developed by Baylor College of Medicine and Tessa.

• Tessa Therapeutics Announces Presentation of Autologous and Allogeneic Cell Therapy Data at 2021 ASH Annual Meeting

  11/3/2021

  Tessa Therapeutics Ltd. announced that data from its ongoing autologous and allogeneic cell therapy studies targeting lymphomas has been accepted for two separate poster presentations at the 63rd American Society of Hematology Annual Meeting and Exposition being held from December 11-14, 2021.

• Tessa Therapeutics Announces Positive, Topline Data from Ongoing Phase 1 Trial of Allogeneic, “Off-the-Shelf” Cell Therapy, in Patients with Relapsed or Refractory CD30-Positive Lymphoma

  5/14/2021

  Data to be Presented Today at the ASGCT 24th Annual Meeting Demonstrated No Dose-Limiting Toxicity with Encouraging Clinical Activity in First 5 Patients Treated; Final Data Readout Expected by End of 2021

• Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study

  4/30/2021

  Tessa Therapeutics Ltd., a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced enrollment of 12 patient Pilot cohort of its Phase 2 trial in relapsed / refractory Classical Hodgkin Lymphoma.

• Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy

  1/18/2021

  Tessa Therapeutics, a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced that the European Medicines Agency has granted PRiority MEdicines designation to the company's lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma.

• Tessa Therapeutics Appoints David McIntyre as Chief Financial Officer

  12/17/2020

   Tessa Therapeutics (Tessa) , a clinical-stage cell therapy company developing next-generation cancer treatments, today announced the appointment of David McIntyre as its Chief Financial Officer. Mr. McIntyre brings over 25 years of global financial, operational and legal experience, including over 10 yea

• 

  Clinical Catch-Up: August 3-7

  8/10/2020

  It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.

• Tessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Autologous CD30 CAR-T Cell Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma

  8/6/2020

  Tessa Therapeutics (Tessa) , a clinical-stage cell therapy company developing next-generation cancer treatments, today announced the publication of results in the Journal of Clinical Oncology from two investigator-sponsored Phase 1/2 trials led by Baylor College of Medicine and the University of North Carolina Lineberger Comprehe

• Tessa Therapeutics Announces New Executive Leadership

  5/4/2020

  Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments, today announced that Jeffrey H. Buchalter will assume the role of Chief Executive Officer, and Göran A. Ando will become Chairman of the Board, with immediate effect.

• Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma

  2/27/2020

  Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments, today announced that the Company's investigational CD30-directed autologous chimeric antigen receptor T cell (CD30 CAR-T) therapy has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory CD30-positive classical Hodgkin lymphoma (cHL).

• Tessa Therapeutics to Open 90,000 Square Foot Commercial-Scale Cell Therapy Manufacturing Facility in Singapore in 2020

  12/19/2019

  Tessa Therapeutics (Tessa), a clinical-stage cell therapy company focused on the development of innovative cell therapies to treat cancer, today announced plans to open a 90,000 square foot commercial-scale cell therapy manufacturing facility in Singapore by end-2020, which will be one of the leading commercial-scale cell therapy manufacturing facilities in Asia.

• Tessa Therapeutics and China-Singapore Guangzhou Knowledge City Form Landmark US$120 Million Joint Venture in China to Develop Innovative Cell Therapies for Cancer

  6/13/2019

  Tessa Therapeutics (Tessa), announced that it will establish a joint venture with China-Singapore Guangzhou Knowledge City (CSGKC).

• 

  Tessa Therapeutics Forges $120 Million Joint Venture to Develop Cell Therapies in China

  6/13/2019

  The collaboration with China-Singapore Guangzhou Knowledge City will focus on the most prevalent cancers in China.
• 

  BioSpace's Global Biopharma Roundup: May 2

  5/2/2019

  Pharma, biotech and life science companies from across the globe share data and progress on pipelines and other company events.

• Tessa Therapeutics, in Collaboration with Baylor College of Medicine, Presents Preclinical Results Showing Enhanced T Cell Responses Against HER2-Positive Solid Tumors Using Novel Combination CAR T Cell Therapy

  4/30/2019

  Preclinical, 'proof-of-concept' results for a novel 'all-in-one' immunotherapy for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-positive solid tumors

• 

  BioSpace' s Global Biopharma Roundup: April 18

  4/18/2019

  Pharma and biotechs from across the globe share news, pipeline updates, with stories from Vetter, Atomwise, Tessa, GenSight, and more.

• Tessa Therapeutics Announces Collaboration with Merck Investigating the Combination of KEYTRUDA® (pembrolizumab) and Virus-Specific T Cell Therapy Targeting Human Papillomavirus in Cervical Cancer

  4/16/2019

  The collaboration will evaluate the safety and efficacy of Tessa's armored human papillomavirus-specific T cell (HPVST) therapy combined with Merck's KEYTRUDA® (pembrolizumab) to address the limited number of effective treatment options for metastatic or recurrent cervical cancer

• 

  BioSpace Movers and Shakers: March 8

  3/8/2019

  Perhaps the biggest mover and shaker announcement this week was the unexpected resignation of Scott Gottlieb, commissioner of the U.S. Food and Drug Administration. Gottlieb will leave his post later this month to spend more time with his family.

• Tessa Therapeutics Names Biopharma Veteran Jeffrey H. Buchalter to Board of Directors

  2/28/2019

  Mr. Buchalter brings over thirty years' experience in the biopharmaceutical industry, with strong corporate leadership and an extensive background in the commercial positioning and development of therapeutics in oncology